Myeloma UK Impact Report 2025: For today and for tomorrow

Myeloma UK funds research and advocates for people living with myeloma across the UK. Their 2025 impact report covers multiple landmark NHS drug approvals including a world-first BVD approval, a new £1m research grant programme, the launch of a Precursor Framework for myeloma prevention, and a symptom awareness campaign reaching 1.6 million people.

Report snapshot
42 Views

📋About

Research grants and fellowships, MyeTRIAL Partnership, Clinical Service Excellence Programme, Peer Buddy service, Myeloma Helpline (260+ languages), Knowledge is Power awareness campaign, drug appraisal advocacy, Precursor Framework

📊Key Metrics

Multiple NHS drug approvals secured in 2025 including world-first BVD approval, benefitting thousands of myeloma patients Key Metric 1
UK's leading myeloma charity working to prevent, treat and help people live well with myeloma through research, advocacy and patient support Key Metric 2
Funding pioneering research, securing NHS treatment access, supporting patients and carers, and raising awareness of myeloma symptoms and precursor conditions Key Metric 3

Key Outcomes

  • IsaVRD quadruplet treatment approved in England, Wales and Scotland — 63% of patients still in remission after five years in trials
  • Myeloma Awareness Week campaign reached over 1.6 million people with symptom awareness content
  • 86 hospitals accredited through the Clinical Service Excellence Programme since 2015; helpline now accessible in over 260 languages

📍Geography

UK-Wide

2026 Enhanced

Impact — Winter 2026

Total income £18,180,000 and total expenditure £18,560,000 (year ended 31 December 2024, charity no. 1084958 England/Wales and SC039654 Scotland); in 2024 spent £3.8m on charitable activities including £1,079,000 on research, £1,366,000 on EB Community Support, £943,000 on public education, £270,000 on EB healthcare and £185,000 on respite breaks
Key Metric 1
700+ members supported through in-person visits and support calls in 2025; 697 support grants allocated in 2025 for essential items including specialist clothing, cooling fans and sheepskin liners; 2 new holiday homes purchased in 2025 with over 700 guests enjoying holiday homes; £34,000 raised through 2025 winter 'The Longest Night' appeal
Key Metric 2
Largest global investment in EB research to date: multi-million-pound drug repurposing trial provisionally agreed with LifeArc partner at Guy's and St Thomas' NHS Foundation Trust and King's College London; EB Priorities Setting Partnership study completed mapping global research priorities for all four main EB forms
Key Metric 3
£34,000 raised in 2025 winter appeal supporting families like Darcie's with specialist items, emotional support and research; 697 support grants delivered in 2025; first Members Connect event in Northern Ireland; EB Priorities Setting Partnership study completed providing global research roadmap
2025 Enhanced

Impact Report 2025

22,507 households helped through RBL casework and specialist support services across 66 countries
Key Metric 1
22,600 grants given to those in need, totalling £11.8 million
Key Metric 2
733 beneficiaries represented at tribunals, resulting in £24.5 million in War Pensions awards
Key Metric 3
1,548 new families living with dementia supported by RBL Admiral Nurses service
2025 Enhanced

Our Impact 2024-25

3,600 blind veterans received support across the UK; 447 new blind veterans started receiving support in 2024/25
Key Metric 1
1,598 referrals to rehabilitation services completed; 313 veterans received assistive technology training
Key Metric 2
997 volunteers donated 26,824 hours of support; befriending service awarded Quality in Befriending Excellence — one of only 11 organisations in the UK to achieve this
Key Metric 3
1,831 National Creative Wellbeing Project packs issued to help veterans reconnect with creativity and independence